These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 29106714)

  • 1. Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque Psoriasis.
    Langley RG; Kasichayanula S; Trivedi M; Aras GA; Kaliyaperumal A; Yuraszeck T; Gibbs J; Gibbs M; Kricorian G; Paller AS
    J Clin Pharmacol; 2018 Mar; 58(3):340-346. PubMed ID: 29106714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
    Elewski B; Leonardi C; Gottlieb AB; Strober BE; Simiens MA; Dunn M; Jahreis A
    Br J Dermatol; 2007 Jan; 156(1):138-42. PubMed ID: 17199580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
    Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study.
    Xie F; Wang R; Zhao ZG; Meng XF; Lin BW; Yang J; Wang WJ; Ding XY; Yang Y; Zhao H; Li CX; Li HJ; Zhou Y
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):943-947. PubMed ID: 29270758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.
    Gerdes S; Thaçi D; Griffiths CEM; Arenberger P; Poetzl J; Wuerth G; Afonso M; Woehling H
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):420-427. PubMed ID: 28960486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis.
    Lee JH; Youn JI; Kim TY; Choi JH; Park CJ; Choe YB; Song HJ; Kim NI; Kim KJ; Lee JH; Yoo HJ
    BMC Dermatol; 2016 Jul; 16(1):11. PubMed ID: 27455955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.
    Griffiths CEM; Thaçi D; Gerdes S; Arenberger P; Pulka G; Kingo K; Weglowska J; ; Hattebuhr N; Poetzl J; Woehling H; Wuerth G; Afonso M
    Br J Dermatol; 2017 Apr; 176(4):928-938. PubMed ID: 27787890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis.
    Bader-Meunier B; Krzysiek R; Lemelle I; Pajot C; Carbasse A; Poignant S; Melki I; Quartier P; Choupeaux L; Henry E; Treluyer JM; Belot A; Hacein-Bey-Abina S; Urien S
    Semin Arthritis Rheum; 2019 Jun; 48(6):1014-1018. PubMed ID: 30396593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept treatment for children and adolescents with plaque psoriasis.
    Paller AS; Siegfried EC; Langley RG; Gottlieb AB; Pariser D; Landells I; Hebert AA; Eichenfield LF; Patel V; Creamer K; Jahreis A;
    N Engl J Med; 2008 Jan; 358(3):241-51. PubMed ID: 18199863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
    Blauvelt A; Papp KA; Griffiths CEM; Puig L; Weisman J; Dutronc Y; Kerr LF; Ilo D; Mallbris L; Augustin M
    Am J Clin Dermatol; 2017 Apr; 18(2):273-280. PubMed ID: 28074446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.
    Landells I; Paller AS; Pariser D; Kricorian G; Foehl J; Molta C; Freundlich B
    Eur J Dermatol; 2010; 20(3):323-8. PubMed ID: 20185386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
    Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
    Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast.
    Bagel J; Samad AS; Stolshek BS; Aras GA; Chung JB; Kricorian G; Kircik LH
    J Drugs Dermatol; 2018 Oct; 17(10):1078-1082. PubMed ID: 30365588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
    J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
    Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
    Paller AS; Hong Y; Becker EM; de Lucas R; Paris M; Zhang W; Zhang Z; Barcellona C; Maes P; Fiorillo L
    J Am Acad Dermatol; 2020 Feb; 82(2):389-397. PubMed ID: 31408686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis.
    Paller AS; Siegfried EC; Pariser DM; Rice KC; Trivedi M; Iles J; Collier DH; Kricorian G; Langley RG
    J Am Acad Dermatol; 2016 Feb; 74(2):280-7.e1-3. PubMed ID: 26775775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
    Sterry W; Ortonne JP; Kirkham B; Brocq O; Robertson D; Pedersen RD; Estojak J; Molta CT; Freundlich B
    BMJ; 2010 Feb; 340():c147. PubMed ID: 20124563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.